US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi: 10.3322/caac.21357.
   PubMed Web of Science ®Google Scholar
• Kanas G, Ge W, Quek RGW, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025.Leuk Lymphoma. 2022;63(1):54–63. doi: 10.1080/10428194.2021.1975188.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. doi: 10.1056/NEJMra2027612.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Jacobson CA, Ghobadi A, et al. 5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-Cell lymphoma (ZUMA-1). Blood. 2023;141(19):2307–2315. doi: 10.1182/blood.2022018893.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi: 10.1016/S1470-2045(21)00375-2.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-Cell lymphomas (LBCL). Blood. 2021;138(Suppl 1):2840–2840. doi: 10.1182/blood-2021-148948.
   Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi: 10.1016/S1470-2045(20)30225-4.
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–2231. doi: 10.1056/NEJMoa2206913.
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065. doi: 10.1016/S1470-2045(22)00335-7.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell–engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238–2247. doi: 10.1200/jco.22.01725.
   PubMed Web of Science ®Google Scholar
• Kim W-S, Kim TM, Cho S-G, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2. Blood. 2022;140(Suppl 1):1070–1071. doi: 10.1182/blood-2022-158406.
   Google Scholar
• Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533–543. doi: 10.1182/bloodadvances.2021005794.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi: 10.1056/NEJMoa2115304.
   PubMed Web of Science ®Google Scholar
• Betts KA, Thuresson PO, Felizzi F, et al. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. J Comp Eff Res. 2020;9(14):1003–1015. doi: 10.2217/cer-2020-0057.
   PubMed Web of Science ®Google Scholar
• Bastos-Oreiro M, de Las Heras A, Presa M, et al. Cost-Effectiveness analysis of axicabtagene ciloleucel vs. Tisagenlecleucel for the management of relapsed/refractory diffuse large B-cell lymphoma in Spain. Cancers. 2022;14(3):538. doi: 10.3390/cancers14030538.
   PubMed Web of Science ®Google Scholar
• Liu R, Oluwole OO, Diakite I, et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458–468. doi: 10.1080/13696998.2021.1901721.
   PubMed Web of Science ®Google Scholar
• Felizzi F, Launonen A, Thuresson PO. Approximation of Long-Term survival with polatuzumab vedotin plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-Cell lymphoma: results based on the GO29365 trial. Pharmacoecon Open. 2023;7(1):37–46. doi: 10.1007/s41669-022-00339-1.
   PubMed Web of Science ®Google Scholar
• Ho R, Launonen A. MSR38 comparison of mixture-cure model versus standard parametric survival model in 1L diffuse large B-cell lymphoma. Value in Health. 2022;25(7):S525. doi: 10.1016/j.jval.2022.04.1245.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi: 10.1001/jama.2016.12195.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi: 10.1056/NEJMp1405158.
   PubMed Web of Science ®Google Scholar
• Microsoft Corporation. Microsoft Excel. 2016 [cited 2023 June 28]. https://office.microsoft.com/excel
   Google Scholar
• Centers for Medicare & Medicaid Services. ASP Drug Pricing Files. 2023. [cited 2023 June 28]. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2023-asp-drug-pricing-files
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule search. 2022 [cited 2023 Aug 08]. https://www.cms.gov/apps/physician-fee-schedule/overview.aspx
   Google Scholar
• Tkacz J, Garcia J, Gitlin M, et al. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk Lymphoma. 2020;61(7):1601–1609. doi: 10.1080/10428194.2020.1734592.
   PubMed Web of Science ®Google Scholar
• Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s–80s. doi: 10.1200/JOP.2011.000469.
   PubMedGoogle Scholar
• US Bureau of Labor Statistics. How do retirement plans for private industry and state and local government workers compare? 2023 [cited 2023 July 04]. https://www.bls.gov/opub/btn/volume-12/how-do-retirement-plans-for-private-industry-and-state-and-local-government-workers-compare.htm
   Google Scholar
• US Bureau of Labor Statistics. Average weekly hours and overtime of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. 2023 [cited 2023 Mar 05]. https://www.bls.gov/news.release/empsit.t18.htm
   Google Scholar
• Guy GP, Jr, Yabroff KR, Ekwueme DU, et al. Economic burden of chronic conditions among survivors of cancer in the United States. J Clin Oncol. 2017;35(18):2053–2061. doi: 10.1200/jco.2016.71.9716.
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. News release. 2023 [cited 2023 Mar 7]. https://www.bls.gov/news.release/pdf/empsit.pdf
   Google Scholar
• HCUP National Inpatient Sample (NIS). Healthcare cost and utilization project (HCUP). Rockville (MD): Agency for Healthcare Research and Quality; 2017 [cited 2023 June 28]. www.hcup-us.ahrq.gov/nisoverview.jsp
   Google Scholar
• US Food and Drug Administration. POLIVY® US Prescribing Information. 2023 [cited 2023 July 14]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf
   Google Scholar
• US Bureau of Labor Statistics. CPI for all urban customers, medical care in U.S. city average. 2023 [cited 2023 May 05]. https://data.bls.gov/timeseries/CUUR0000SAM
   Google Scholar
• Genentech, Inc. Data on file.
   Google Scholar
• Keating SJ, Gu T, Jun MP, et al. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022;28(7):404.e1–404.e6. doi: 10.1016/j.jtct.2022.03.021.
   PubMedGoogle Scholar
• Purdum A, Tieu R, Reddy SR, et al. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229–1236. doi: 10.1634/theoncologist.2018-0490.
   PubMed Web of Science ®Google Scholar
• Felizzi F, Paracha N, Pöhlmann J, et al. Mixture cure models in oncology: a tutorial and practical guidance. Pharmacoecon Open. 2021;5(2):143–155. doi: 10.1007/s41669-021-00260-z.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71. doi: 10.1186/s13045-020-00900-7.
   PubMed Web of Science ®Google Scholar
• Arias E, Xu J, Tejada-Vera B, et al. National vital statistics reports: from the centers for disease control and prevention, national center for health statistics, national vital statistics system. Natl Vital Stat Rep. 2022;71(2):1–18.
   Google Scholar
• Jakobsen LH, Bøgsted M, Brown P, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish Population-based study. J Clin Oncol. 2017;35(7):778–784. doi: 10.1200/jco.2016.70.0765.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• National Institute of Health and Care Excellence (NICE) Guidance. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. 2023 [cited 2023 Apr 06]. https://www.nice.org.uk/guidance/ta874/resources/polatuzumab-vedotin-in-combination-for-untreated-diffuse-large-bcell-lymphoma-pdf-82613673152197
   Google Scholar
• Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–609. doi: 10.1182/blood.2020006578.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941. doi: 10.1016/j.jval.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care. 2007;45(12):1162–1170. doi: 10.1097/MLR.0b013e31814848f1.
   PubMed Web of Science ®Google Scholar
• Kite Pharma Inc. YESCARTA® U.S. prescribing Information. 2022 [2023 May 05]. https://www.fda.gov/media/108377/download
   Google Scholar
• Kambhampati S, Saumoy M, Schneider Y, et al. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 2022;140(25):2697–2708. doi: 10.1182/blood.2022016624.
   PubMed Web of Science ®Google Scholar
• Fu YH, Wu SJ, Tan ECH, et al. Cost-effectiveness analysis of frontline treatment with polatuzumab vedotin in diffuse large B-cell lymphoma. Blood. 2022;140(Suppl 1):10808–10809. doi: 10.1182/blood-2022-162980.
   Google Scholar
• Vijenthira A, Kuruvilla J, Crump M, et al. Cost-effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(8):1577–1589. doi: 10.1200/jco.22.00478.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi: 10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence (NICE) Guidance. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. 2019 [cited 2023 May 02]. https://www.nice.org.uk/guidance/ta567/resources/tisagenlecleucel-for-treating-relapsed-or-refractory-diffuse-large-bcell-lymphoma-after-2-or-more-systemic-therapies-pdf-82607087377861
   Google Scholar
• Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073. doi: 10.1200/jco.2013.51.5866.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827. doi: 10.1093/annonc/mdy203.
   PubMed Web of Science ®Google Scholar
• Shi Q, Schmitz N, Ou FS, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36(25):2593–2602. doi: 10.1200/jco.2018.77.9124.
   PubMed Web of Science ®Google Scholar
• Choe JH, Abdel-Azim H, Padula WV, et al. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956-e2245956. doi: 10.1001/jamanetworkopen.2022.45956.
   Web of Science ®Google Scholar
• Kelkar AM, Cliff ERS, Jacobson CA, et al. Cost-effectiveness of CD19 chimeric antigen receptor T-cell (CAR-T) therapy versus autologous stem cell transplantation (ASCT) for high-risk diffuse large B-cell lymphoma (DLBCL) in first relapse. J Clin Oncol. 2022;40(16 Suppl):7537–7537. doi: 10.1200/JCO.2022.40.16_suppl.7537.
   Web of Science ®Google Scholar